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SUMMARY – The aim is to present data on the treatment and follow-up in a cohort of patients 
with pediatric thyroid cancer who underwent total thyroidectomy and received postoperative radioac-
tive iodine (I-131) therapy. The study was conducted in a tertiary high-volume thyroid center, in 
 pediatric patients with differentiated thyroid cancer who were consecutively treated during the 1965-
2015 period. A total of 45 patients aged ≤18 years having undergone total thyroidectomy with or 
without selective neck dissection were included in the study. Decision on postoperative I-131 ablation 
was based on tumor characteristics, postoperative thyroglobulin level, preablative whole body scintig-
raphy, and/or neck ultrasound. Median age at diagnosis was 15 years. The presence of cervical lymph 
node metastases was significantly associated with papillary thyroid cancer, larger tumor size, involve-
ment of two thyroid lobes, and multifocal disease. The presence of distant metastases was significantly 
associated with larger tumor size. None of the patients died during follow-up period, and the 5-year 
and 10-year overall survival rates were 100%. The 5-year and 10-year progression-free survival (PFS) 
rates were 87% and 73%, respectively. Male gender (p=0.046), age ≤15 years (p=0.029) and tumor size 
>15 mm (p=0.042) were significantly associated with inferior PFS. A significant positive trend of 
 increase in the number of newly diagnosed patients was observed over time (p=0.011). Clinical man-
agement of pediatric thyroid cancer is challenging, especially in the light of increasing incidence in 
this population. Male patients younger than 15 years and with tumors of more than 15 mm in size 
require additional caution due to lower PFS observed.
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Introduction
While thyroid cancer is the most common endo-
crine tumor in adults, it is much less frequent in chil-
dren and adolescents, accounting for 1.8% of all dif-
ferentiated thyroid cancer (DTC) cases1,2. DTC is 
generally more advanced at the time of diagnosis in 
children and adolescents than in adults, with neck 
lymph node metastasis and distant metastasis (mostly 
in lungs) occurring in 39%-90% and 6%-41% of pa-
tients, respectively3-6. Despite advanced stage at diag-
nosis and high recurrence rate (11%-45%), the prog-
nosis of pediatric thyroid cancer is more favorable than 
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in adults, with only sporadic cases with fatal outcomes 
(less than 5%)7-10. As survival rates suggest, thyroid 
cancer in children and adolescents is genetically differ-
ent from the adult type, with important clinical, mo-
lecular and pathologic divergences, which could prove 
to be a contributing factor in treatment efficacy9. Cur-
rent standard of care for these patients is surgery (total 
thyroidectomy)11. Application rate of postoperative 
treatment with radioactive iodine (I-131) varies among 
centers, but is generally becoming more common in 
the treatment of pediatric patients12. Studies regarding 
I-131 therapy in children are limited and mostly of 
low-level evidence, especially in the adjuvant setting13. 
Furthermore, there are no established standardized ac-
tivities of I-131 for the pediatric population, and these 
are usually determined based on the individual physi-
cian’s decision, especially in patients with disseminated 
disease10. Children and adolescents with thyroid can-
cer are shown to have better progression-free survival 
(PFS) after I-131 therapy than adult patients, thus it is 
necessary to assess the potential risk/benefit ratio prior 
to the application of therapy5,8. In the frame of larger 
proportion of patients with pediatric DTC that receive 
high activities of I-131 and long overall survival (OS), 
issues have arisen regarding long-term adverse effects, 
with particular accent on the development of second-
ary malignancies. Here we present clinicopathologic 
data on 45 pediatric patients treated with I-131 for 
thyroid cancer collected over a 50-year period.
Patients and Methods
The study was conducted in a tertiary high-volume 
thyroid center, based on data on all pediatric patients 
with DTC that were evaluated between 1965 and 
2015. Inclusion criteria were as follows: £18 years of 
age at diagnosis; and diagnosis of DTC confirmed by 
histopathologic analysis (total thyroidectomy or lobec-
tomy). There were no additional exclusion criteria, and 
a total of 45 patients were included in the study. The 
study was conducted in compliance with ethical stan-
dards set by the institutional Ethics Committee and 
the Helsinki Declaration from 1975, as revised in 
1983. Decisions with respect to postoperative I-131 
ablation were based on histopathologic tumor charac-
teristics, postoperative thyroglobulin (Tg) level, post-
operative anti-Tg antibody (TgAb) level, preablative 
whole body scintigraphy (WBS), and/or neck ultra-
sound. Neck ultrasound was performed in all patients 
after the introduction of the method in 1978, and 
preablative WBS was selectively performed to esti-
mate the mass of the possible thyroid remnant after 
surgery. Postoperative WBS was done in all patients 
that received I-131 therapy. Multiple I-131 therapies 
were administered in cases of ablation failure, defined 
as the presence of remnant thyroid tissue (visible ac-
cumulation of I-131) in the thyroid bed and cervical 
region on WBS (Tg level, TgAb level, and neck ultra-
sound were used as additional diagnostic criteria). Pa-
tients were regularly followed-up for disease recur-
rence and dissemination at 6- to 12-month intervals, 
until the study cut-off date on December 31, 2016.
All procedures performed in studies involving hu-
man participants were in accordance with ethical stan-
dards set by the institutional and/or national research 
committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical stan-
dards.
Statistical analysis
The normality of distribution of numerical vari-
ables was tested using the Shapiro-Wilk test. Numeri-
cal variables were presented as median and interquar-
tile range (IQR), and categorical variables were pre-
sented as number and percentage. Numerical variables 
between groups were compared using the Mann 
Whitney U test and categorical variables were com-
pared between groups using the χ2-test. Spearman 
rank correlation was used to test correlation between 
numerical variables. Poisson regression was used to 
test the trend of increase in the number of cases over 
time. Survival analyses were performed using the 
methods of Kaplan and Meier and the Cox-Mantel 
log-rank test14. Cut-off point for numerical variables 
was determined using ROC curve analysis. Data were 
screened using custom made MS Excel workbook15 
and re-analyzed using MedCalc Statistical Software 
version 16.2.0 (MedCalc Software bvba, Ostend, Bel-
gium). The values of p<0.05 were considered signifi-
cant. Optimal cut-off points for transforming numeri-
cal variables into dichotomous variables for the pur-
pose of survival analysis were determined using ROC 
curve analysis with PFS status as a classification vari-
able. Age >15 years and tumor size >15 mm showed 
best survival discriminatory properties.
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Table 2. Tumor features in patients with or without lymph node (LN) metastases
Without LN involvement With LN involvement p value
Number of patients 16 23 -
PTC diagnosis 12/16 (75%) 23/23 (100%) 0.022
Age (yrs) 15.5 IQR (14-16) 14 IQR (13-16.5) 0.443
Male gender 0/16 (0%) 4/23 (17.4%) 0.130
Tumor size (mm) 15 IQR (9-22) 26 IQR (18.8-33.5) 0.028
Capsule infiltration 1/9 (11.1%) 6/13 (46.2%) 0.165
Involvement of both lobes 1/12 (8.3%) 7/15 (46.7%) 0.043
Multinodal thyroid disease 1/12 (8.3%) 8/16 (50%) 0.039
Distant metastases 0/15 (0%) 6/23 (26.1%) 0.063
Postoperative Tg 68.7 IQR (44.1-93.4) 13.6 IQR (8.8-40.8) 0.248
Patients receiving I131 13/14 (92.9%) 22/23 (95.7%) 1.000
Total RAI activity 99.5 IQR (55-161.8) 150 IQR (100-258.5) 0.064
Number of applications 1 IQR (1-1.8) 2 IQR (1-2) 0.146
Overall survival 100% 100% -
5-year PFS 85.9% 84.6% 0.620
PTC = papillary thyroid cancer; Tg = thyroglobulin; RAI = radioiodine therapy; PFS = progression free survival; IQR = inter-
quartile range
Table 1. Characteristics of pediatric patients with 
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Results
Patient characteristics
A total of 45 pediatric patients with DTC were 
evaluated, representing 1.5% of all patients in DTC 
database. Median age at diagnosis was 15 years, IQR 
13-16. There were 40 (89%) female and five (11%) 
male patients, yielding a female to male ratio of 8:1. 
Patient characteristics are shown in Tables 1-3. The 
number of patients diagnosed with DTC was stable 
until the last decade, when a substantial increase in the 
number of newly diagnosed cases was observed. Over-
all, there was a significant positive trend of increase in 
the number of newly diagnosed patients over time 
(p=0.011), as shown in Figure 1. Patients were further 
divided into tertiles of the study period to analyze 
whether outcomes differed in patients treated in dif-
ferent time periods. We observed no significant differ-
ence in outcomes between these patient groups 
(p=0.432), as shown in Figure 2. While the majority of 
patients received I-131 (91%), the applied activity and 
number of applications varied, reflecting tumor spe-
cific features that guided therapeutic approach. Medi-
an total I-131 activity was 3700 MBq (100 mCi) (IQR 
65-209), and median number of applications was 1 
(IQR 1-2). Median postoperative Tg was 19.4 ng/mL 
(IQR 13.6-68).
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Tumor characteristics
The median tumor size was 20.5 mm (IQR 11-28), 
and larger tumor size positively correlated with total 
I-131 activity (Rho 0.46, p=0.016) and number of 
I-131 applications (Rho=0.046, p=0.017). The pres-
ence of cervical lymph node metastasis (LNM) was 
significantly associated with papillary thyroid cancer 
(PTC) histology (66% vs. 0% for PTC and follicular 
thyroid cancer (FTC), respectively; p=0.022), larger 
tumor size (26 mm vs. 15 mm for presence and ab-
sence of LNM; p=0.028), involvement of two thyroid 
lobes (88% vs. 42% for bilobar and unilobar tumor, re-
spectively; p=0.043) and multifocal tumor (89% vs. 
42% for multi- and unifocal tumor, respectively; 
Table 3. Tumor features in patients with and without distant metastases
Without distant metastases With distant metastases p value
Number of patients 36 6 -
PTC diagnosis 31/35 (88.6%) 6/6 (100%) 1.000
Age (yrs) 15 IQR (13.8-16) 15 IQR (13.3-16.8) 0.913
Female gender 33/36 (91.7%) 5/6 (83.3%) 0.474
Tumor size (mm) 20 IQR (10-24.3) 50 IQR (44.8-51.3) 0.002
Capsule infiltration 5/20 (25%) 2/2 (100%) 0.091
Involvement of both lobes 7/24 (29.2%) 2/4 (50%) 0.574
Multinodal thyroid disease 8/25 (32%) 2/4 (50%) 0.592
Cervical lymph node involvement 17/32 (53.1%) 6/6 (100%) 0.063
Postoperative Tg 43.7 IQR (15.5-80.5) 13.6 IQR (13.6-13.6) 0.480
Patients receiving I-131 32/35 (91.4%) 6/6 (100%) 1.000
Total RAI activity 100 IQR (55-167.5) 532.5 IQR (346.3-730) <0.001
Number of applications 1 IQR (1-2) 5.5 IQR (2.8-6.8) <0.001
Overall survival 100% 100% -
5-year PFS 86.8% 83.3% 0.631
PTC = papillary thyroid cancer; Tg = thyroglobulin; RAI = radioiodine therapy; PFS = progression free survival; IQR = inter-
quartile range
Fig. 1. The number of patients diagnosed with 
differentiated thyroid cancer (DTC) was stable over time 
until the last decade, when a substantial increase in the 
number of newly diagnosed cases was observed. There was 
a significant positive trend of increase in the number of 
DTC patients over time. Time is shown in 5-year 
intervals.
Fig. 2. Analysis of patients divided into tertiles  
of the study period.
PFS = progression free survival
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Fig. 3. (A) Progression free survival (PFS) curve for all patients; 5-year PFS was 87%; (B) PFS curve by gender; 
male gender was significantly associated with inferior PFS (hazard ratio [HR] 4.22, p=0.046); (C) PFS by age; age 
≤15 years was significantly associated with inferior PFS (HR 7.18, p=0.029); (D) PFS by tumor size; tumor size  
>15 mm was significantly associated with inferior PFS (HR 6.29, p=0.042).
p=0.039). A trend toward statistical significance was 
observed for association of LNM and presence of dis-
tant metastases (26% vs. 0% of patients for presence 
and absence of LNM, respectively; p=0.063), as well as 
for association of LNM and higher total I-131 activity 
(5500 MBq [150 mCi] vs. 3700 MBq [100 mCi] for 
presence and absence of LNM, respectively; p=0.064). 
The presence of distant metastases was significantly 
associated with larger tumor size (50 mm vs. 20 mm 
for presence and absence of distant metastases, respec-
tively; p=0.002), higher total I-131 activity (19720 
MBq [533 mCi] vs. 3700 MBq [100 mCi] for pres-
ence and absence of distant metastases, respectively; 
p<0.001) and higher number of I-131 activity applica-
tions (6 vs. 1 for presence and absence of distant me-
tastases, respectively; p<0.001). Tumors infiltrating 
capsule were significantly larger in size (median 33 vs. 
14 mm for infiltrating and non-infiltrating tumors, re-
spectively; p=0.01). No other significant associations 
were observed.
Survival analyses
The median follow-up of our cohort was 5.9 years. 
None of the patients died during the follow-up period. 
Five-year and 10-year OS rates were 100% (median 
OS was not reached). No secondary malignancies were 
detected during follow-up, however, 9 relapses were 
observed. All relapsing patients experienced recur-
rence of disease in the neck, while three patients ad-
ditionally had lung metastasis. Median PFS was not 
reached, with 5-year PFS rate of 87% and 10-year PFS 
rate of 73%, as shown in Figure 3A. Male gender (haz-
ard ratio [HR] 4.22, p=0.046), age ≤15 years (HR 7.18, 
p=0.029), and tumor size >15 mm (HR 6.29, p=0.042) 
were significantly associated with inferior PFS, as 
shown in Figure 3B, Figure 3C, and Figure 3D, re-
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spectively. I-131 activity higher than 4366 MBq (118 
mCi) (HR 8.87, p=0.001), and more than one I-131 
application necessary for disease control in the setting 
of more advanced initial disease (HR 11.37, p=0.003) 
were also associated with inferior PFS. There was no 
statistically significant effect of histopathologic diag-
nosis, capsule infiltration, number of tumor focuses, 
presence of cervical LNM, distant metastases or Tg 
level on PFS.
Discussion
Results of the present study indicated a worrying 
increasing trend in the number of new cases of pediat-
ric DTC, with a substantial number of newly diag-
nosed cases in the last 10 years. The incidence of pedi-
atric DTC appears to be increasing worldwide16. 
However, the observed increase in the number of cases 
during the last decade could have been due to the true 
rising incidence of pediatric DTC, but could also re-
flect other reasons (more patients referred to the insti-
tution, earlier diagnosis and detection of clinically less 
significant tumors). Analyses in this study were based 
on age cut-off of 18 years and were not directly com-
parable to the results of previously published studies 
that used different age cut-offs with the goal of defin-
ing a population of pediatric/young adult patients with 
DTC (17 to 30 years of age, mixed pre-pubertal, post-
pubertal and young adult population)4,7-8,16-21. Larger 
tumors had significantly higher rates of LNM and dis-
tant metastases. Involvement of two thyroid lobes and 
multifocal tumor were also significantly linked with 
higher LNM rates, but the results were not statisti-
cally significant in relation to the initial presence of 
distant metastases. These results are in accordance with 
the study conducted by Kim et al., which found the 
increasing tumor size and multifocal disease to be in-
dependent factors associated with LNM in pediatric 
DTC22.
In pediatric population, the goal of radiation is 
most commonly to eradicate known residual disease 
(micro-metastases), rather than to ablate the normal 
thyroid remnant only10. The increasing trend of I-131 
application in patients under 25 years of age is report-
ed, with percentages of patients receiving I-131 in-
creasing from 4% in 1973 to 62% in 2008. This phe-
nomenon is present despite the increasing proportion 
of patients with low-risk features12. There are many 
data on I-131 use in thyroid cancer patients in 
adults23-32. However, there are no randomized prospec-
tive clinical studies that address the issue of I-131 ben-
efit in pediatric DTC population, dose-response rela-
tionship, or thyroid remnant ablation13.The benefit of 
I-131 in pediatric DTC was confirmed in the studies 
by Handkiewicz-Junak et al. and Chow et al.6,8. How-
ever, even patients with low-risk disease may still be at 
risk of residual cervical disease and they might also 
have indication for adjuvant I-131 therapy10.
The biggest concern in the application of multiple 
and high activities of I-131 is development of second-
ary malignancies. In a population-based analysis by 
Marti et al., which included patients aged <25 years, an 
increased risk of second malignancy was detected after 
I-131 therapy and it was slightly higher in children 
than in adult population12. The greatest risk of second 
primary malignancies occurs within 5 years of diagno-
sis and is higher in younger patients33. The threshold 
activity for the development of secondary malignan-
cies is difficult to determine, however, some studies 
proposed cumulative activities of I-131 above 7400 
MBq (200 mCi) and 11100 MBq (300 mCi)13,34. The 
cumulative activities commonly administered to pa-
tients with distant metastases are usually much higher 
than the proposed thresholds. Regardless of the high 
cumulative activity, no secondary malignancies oc-
curred in our cohort of patients.
As stated before, 9 relapses occurred in this cohort 
of patients. All patients experienced regional recur-
rence, and hematogenous dissemination to the lungs 
occurred in three patients. There were no distant me-
tastases without lymph node involvement, with good 
5-year and 10-year PFS rates of 87% and 73%, respec-
tively. This is in line with previously reported PFS rates 
that are considered to be much better than in adult 
patients6,8,35. Male gender, age 15 years or younger, and 
tumor size of more than 15 mm were significantly as-
sociated with inferior PFS in this cohort of patients. 
Although there was no significant difference in unfa-
vorable disease features between genders or age groups, 
it has been previously reported that they may exist20. It 
is important to stress that significant association of 
larger I-131 activity and higher number of I-131 ap-
plications with inferior PFS is a consequence of more 
aggressive disease presentation mandating a more in-
tensive approach, and should not be interpreted as a 
sign of therapy insufficiency/harm. The prognosis 
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would probably be even worse if I-131 activity was re-
duced or omitted in these patients.
Limitations of our study were retrograde study de-
sign, small number of patients, incomplete number of 
observations for all patients, and long period of data 
collection (50 years). However, our observations repre-
sent a valuable contribution to the pool of knowledge 
about this rare tumor of pediatric age.
In conclusion, the incidence of pediatric thyroid 
cancer appears to be increasing worldwide, although it 
is not yet clear whether this is true increase or it is due 
to better detection of the disease. Male gender, age ≤15 
years, and tumor size >15 mm were significantly asso-
ciated with inferior PFS in this cohort of patients. All 
activities should be carried out in centers which em-
ploy a multidisciplinary team approach and have the 
necessary expertise in the management of pediatric 
thyroid cancer patients.
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Sažetak
DIFERENCIRANI KARCINOM ŠTITNJAČE U PEDIJATRIJSKOJ POPULACIJI (≤18 GODINA):  
POSLIJEOPERACIJSKO LIJEČENJE RADIOAKTIVNIM JODOM (I-131)
M. Prpić, M. Franceschi,T. Jukić, D. Kust, N. Dabelić, T. Varjačić, M. Lucijanić, A. Bolanča i Z. Kusić
Cilj je prikazati podatke o liječenju i praćenju kohorte bolesnika s pedijatrijskim rakom štitnjače, kod kojih je učinjena 
totalna tireoidektomija te provedena poslijeoperacijska terapija radioaktivnim jodom (I-131). Studija je provedena u tercijar-
nom centru za štitnjaču visokog volumena, u bolesnika s pedijatrijskim diferenciranim karcinomom štitnjače koji su liječeni 
konsekutivno u razdoblju od 1965. do 2015. godine. U studiju je bilo uključeno 45 bolesnika (18 godina i mlađi) kod kojih 
je učinjena totalna tireoidektomija sa selektivnom disekcijom vrata ili bez nje. Odluka o indikaciji za provođenje poslije-
operacijske ablacije pomoću I-131 je donesena na temelju karakteristika tumora, poslijeoperacijske razine tireoglobulina, 
predablacijske scintigrafije cijelog tijela i/ili ultrazvuka vrata. Medijan dobi pri postavljanju dijagnoze je iznosio 15 godina. 
Prisutnost metastaza u limfne čvorove vrata je bila značajno povezana s papilarnim rakom štitnjače, većom veličinom tumo-
ra, zahvaćenosti dvaju režnjeva štitnjače te multifokalnom bolešću. Prisutnost udaljenih metastaza je bila značajno povezana 
s većom veličinom tumora. Tijekom razdoblja praćenja nijedan bolesnik nije preminuo, a 5-godišnje i 10-godišnje stope 
ukupnog preživljenja su iznosile 100%. Petogodišnje i 10-godišnje preživljenje bez progresije bolesti (PPB) je iznosilo 87% 
odnosno 73%. Muški spol (p=0,046), dob ≤15 godina (p=0,029) i veličina tumora >15 mm (p=0,042) su bili značajno pove-
zani s nižim PPB. Zamijećen je značajan trend porasta broja novodijagnosticiranih bolesnika tijekom vremena (p=0,011). 
Klinički postupak u populaciji dece s diferenciranim karcinomom štitnjače je izazovan, osobito u svjetlu porasta incidencije 
u ovoj populaciji. Osobitu pozornost treba posvetiti muškim bolesnicima mlađim od 15 godina s tumorima većim od 15 mm 
zbog opaženog nižeg PPB.
Ključne riječi: Jod; Karcinom štitnjače, papilarni; Adenokarcinom, folikularni; Stopa preživljenja; Dijete; Kontrolna istra-
živanja
